GlassScriptPhysician profile
Alexander Arhets
NPI 1013956853
$13,948.50
in general payments reported to CMS, 2019-2025
20 companies · $2,710 in 2025
The $2,710 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,725 · 2022: $2,278 · 2023: $2,582 · 2024: $4,653 · 2025: $2,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,647 · Consulting Fee: $1,863 · Education: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,647.39 |
| Consulting Fee | $1,862.50 |
| Education | $435.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,719.10 | 2021-2025 | |
| Janssen Biotech, INC. | $2,426.94 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $1,832.72 | 2021-2025 | |
| Amgen INC. | $1,489.40 | 2023-2025 | Repatha, Repatha |
| Regeneron Healthcare Solutions, INC. | $949.40 | 2021-2025 | Dupixent |
| Genzyme Corporation | $552.92 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $286.59 | 2023 | Sotyktu |
| Galderma Laboratories, L.P. | $257.56 | 2021-2025 | Aklief, Nemluvio, Oracea |
| Arcutis Biotherapeutics, INC. | $235.36 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $224.18 | 2021-2024 | Ilumya |
| Dermavant Sciences, INC. | $219.89 | 2024 | Vtama |
| Incyte Corporation | $215.57 | 2022-2025 | Opzelura |
| Organon LLC | $155.68 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $99.04 | 2021 | |
| Leo Pharma INC. | $95.94 | 2023-2025 | Adbry, Anzupgo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $81.05 | 2021-2025 | Bimzelx |
| Lilly USA, LLC | $58.08 | 2022-2024 | Ebglyss, Taltz |
| Organogenesis INC. | $18.15 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.66 | 2024 | Cyltezo |
| Pfizer INC. | $15.27 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Arhets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.